SecBot SecBot

IRON

Disc Medicine, Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001816736 Biotech & Drug Discovery
$80.00 −3.23 (−3.88%)
Nov 13 4:00 PM ET · prev $83.23
Market cap
$3.8B
Mid cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$127.00
+59% · range $92.00–170.00
1 year
−10.8%
from $89.65 · Nov 17
30 days
+1.4%
from $78.93
52-week range
$55.74–94.11
−15% from high · low Oct 14
Avg volume 20D
1.71M
Oct 19 spike 8.49M
Short interest
6.86M
≈15.1% of shares · −8.0%
Days to cover
3.2
at average volume
Insider net
−$17.4M
0 buyers · 5 sellers · since Jun 29
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
35
analyzed by SecBot
SecBot read MIXED 28 reports · 90 days
Balance 6 bearish · 5 bullish · 1 mixed · 16 neutral oldest → newest, height = score
Avg score ·High conf. 22/28

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $17.4M.

  • InstitutionsBULLISH

    Q3 2026: 27 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.812 → −$1.512 over 90 days. 4 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest −8.0% to 6.86M shares. 3.2 days to cover, ≈15.1% of shares.

  • TrendUPTREND

    12% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Assenagon Asset Management S.A.DOUBLED1,119,458$73.3M
Aberdeen Group plcADD597,841$39.1M
BNP PARIBAS FINANCIAL MARKETSADD272,501$17.8M
JANE STREET GROUP, LLCDOUBLED245,230$16.1M
Qube Research & Technologies LtdDOUBLED136,783$9.0M
Nuveen, LLCDOUBLED132,183$8.7M
Pictet Asset Management Holding SATRIM126,233$8.3M
MORGAN STANLEYADD121,264$7.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +59%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Guggenheim
INITIATE
INITIATEBuy
Nov 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 20, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 20, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Oct 20, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Oct 20, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$17.4M
sold · 5 insiders
DateInsiderTypeValue
Nov 10, 2026
Savage William Jacob
Chief Medical Officer
Nov 10, 2026
SELL$1.4M
Oct 21, 2026
Bitterman Kevin
Director
Oct 21, 2026
SELL$1.1M
Oct 21, 2026
Bitterman Kevin
Director
Oct 21, 2026
SELL$920.2K
Oct 21, 2026
Bitterman Kevin
Director
Oct 21, 2026
SELL$21.3K
Oct 20, 2026
Bitterman Kevin
Director
Oct 20, 2026
SELL$229.4K
Oct 20, 2026
Bitterman Kevin
Director
Oct 20, 2026
SELL$190.9K
Oct 20, 2026
Bitterman Kevin
Director
Oct 20, 2026
SELL$4.4K
Oct 19, 2026
Bitterman Kevin
Director
Oct 19, 2026
SELL$474.8K

Earnings setup

Estimates
−$1.51
EPS estimate, this quarter
+17%
estimate change, 90 days
4↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.51-$1.71–-$1.36+12.9%$0.00
Next Q-$1.63-$1.91–-$1.45+10.8%$0.00
Current FY-$6.03-$6.44–-$5.11+8.1%$0.00
Next FY-$6.25-$7.05–-$5.56+11.7%$43.2M

Washington

Corporate Lobbying

4 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
6,862,594
shares short
-8.0%
vs prior settlement
3.2
days to cover
≈15.1%
of shares outstanding
Trading halts
Oct 19, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
William Savage, an officer of Disc Medicine, filed a Form 144 notice of intent to sell 16,035 shares of common stock…
144 · Impact 2/10
Nov 10, 2026 Insider
Savage William Jacob sold 16,035 shares
Chief Medical Officer @ $85.09 ($1.4M)
Nov 5, 2026 SEC
Disc Medicine filed a prospectus supplement for an at-the-market (ATM) equity offering of up to $189.9 million of…
424B5 · Impact 5/10
Nov 5, 2026 SEC
The company highlighted positive Phase 3 APOLLO data for bitopertin in EPP and plans NDA resubmission by end of 2026…
8-K · Impact 5/10
Nov 5, 2026 Earnings
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-st
Nov 4, 2026 Press
Disc Medicine announced it will present data from multiple pipeline programs at the upcoming ASH 2026 meeting…
Impact 3/10
Oct 21, 2026 Insider
Bitterman Kevin sold 13,783 shares
Director @ $80.23 ($1.1M)
Oct 21, 2026 Insider
Bitterman Kevin sold 11,470 shares
Director @ $80.23 ($920.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

35 filings · 8 press releases · 5 bullish · 7 bearish · 23 neutral
All IRON filing & press-release reports (43)